{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:26:20Z","timestamp":1792038380527,"version":"4.4.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Thessaly Central Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction\/objectives<\/jats:title>\n                    <jats:p>Intravenous (IV) immunotherapy sessions are common among patients with rheumatic and musculoskeletal diseases (RMDs). Although immunotherapy plays an important role in disease management, treatment-specific evidence-based nutritional guidance is currently lacking. The present cross-sectional study aimed to evaluate meal quality in patients with RMDs on the days of IV infusion\u00a0immunotherapy sessions and make recommendations on how to improve dietary intake on these days, aiming to achieve ameliorated therapeutic results with less adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 168 outpatient visits on days of IV immunotherapy sessions were included, involving 124 patients with RMDs. Each patient provided detailed information regarding the breakfast they had consumed prior to the session and whether they had brought with them a snack to consume during treatment. The Main Meal Quality Index (MMQI) was used to evaluate meal quality of the breakfast and snack meals of each participant, ranging between 0 to 100, with greater scores indicating better meal quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most patients (74%) reported having consumed breakfast, while only 29% had brought a snack with them for consumption during the sessions. Median MMQI score was 54.4 for breakfast and 50.0 for snack meals, respectively. Breakfast MMQI scores were positively associated with patient age (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.040). Belimumab administration was associated with greater breakfast quality (\u03b2\u2009=\u200922.23,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) compared to rituximab, while tocilizumab use was independently associated with lower snack quality (\u03b2\u2009= \u2212\u200911.96,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030). Patients with systemic lupus erythematosus and axial spondyloarthritis reported consuming a breakfast of better quality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although many patients consumed breakfast prior to their IV infusion immunotherapy sessions, only a small number chose to bring a snack with them. Breakfast quality appeared to be influenced by the type of immunomodulatory therapy patients were receiving. These findings highlight the need for individualized nutritional care and tailored meal guidance on the days of IV treatment, as nutrition may represent a potentially modifiable factor warranting further investigation in relation to therapeutic response and disease outcomes.<\/jats:p>\n                    <jats:p>\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td align=\"left\" colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                \u2022\n                                <jats:italic>On intravenous immunotherapy treatment days, patients consumed energy-dense breakfast and meal snacks, with moderate protein and high saturated fat content.<\/jats:italic>\n                                \u2022\n                                <jats:italic>Meal composition was influenced by the type of immunomodulatory therapy.<\/jats:italic>\n                                \u2022\n                                <jats:italic>Individualized nutrition guidance is essential, promoting high-protein, plant-based, fiber-rich, and unsaturated fat-rich meals, to support therapy and disease outcomes.<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-026-08039-5","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:28:51Z","timestamp":1774434531000},"page":"3757-3770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eating during immunotherapy sessions: a cross-sectional study of meal quality in patients with rheumatic diseases undergoing intravenous therapy with immunomodulators"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-5349","authenticated-orcid":false,"given":"Eleni C.","family":"Pardali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0815-4700","authenticated-orcid":false,"given":"Arriana","family":"Gkouvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5005-1995","authenticated-orcid":false,"given":"Dimitrios G.","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1517-8691","authenticated-orcid":false,"given":"Christos","family":"Cholevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-6576","authenticated-orcid":false,"given":"Christina G.","family":"Katsiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-7902","authenticated-orcid":false,"given":"Dimitrios P.","family":"Bogdanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4167-6595","authenticated-orcid":false,"given":"Maria G.","family":"Grammatikopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"4","key":"8039_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14040888","volume":"14","author":"M Cutolo","year":"2022","unstructured":"Cutolo M, Nikiphorou E (2022) Nutrition and diet in rheumatoid arthritis. Nutrients 14(4):888. https:\/\/doi.org\/10.3390\/nu14040888","journal-title":"Nutrients"},{"issue":"1","key":"8039_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/10408398.2022.2104210","volume":"64","author":"K Gkiouras","year":"2024","unstructured":"Gkiouras K, Grammatikopoulou MG, Myrogiannis I et al (2024) Efficacy of n-3 fatty acid supplementation on rheumatoid arthritis\u2019 disease activity indicators: a systematic review and meta-analysis of randomized placebo-controlled trials. Crit Rev Food Sci Nutr 64(1):16\u201330. https:\/\/doi.org\/10.1080\/10408398.2022.2104210","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"8039_CR3","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.34.1.30","volume":"34","author":"MG Grammatikopoulou","year":"2023","unstructured":"Grammatikopoulou MG, Marakis G, Gkiouras K et al (2023) Fly me to the immune: immunonutrition in rheumatic diseases. Mediterr J Rheumatol 34(1):30. https:\/\/doi.org\/10.31138\/mjr.34.1.30","journal-title":"Mediterr J Rheumatol"},{"issue":"5","key":"8039_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/nu17050752","volume":"17","author":"A Raczy\u0144ska","year":"2025","unstructured":"Raczy\u0144ska A, Leszczy\u0144ska T, Skotnicki P, Koronowicz A (2025) The impact of immunomodulatory components used in clinical nutrition\u2014a narrative review. Nutrients 17(5):752. https:\/\/doi.org\/10.3390\/nu17050752","journal-title":"Nutrients"},{"issue":"27","key":"8039_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946248","volume":"13","author":"A Christovich","year":"2022","unstructured":"Christovich A, Luo XM (2022) Gut microbiota, leaky gut, and autoimmune diseases. Front Immunol 13(27):946248. https:\/\/doi.org\/10.3389\/fimmu.2022.946248","journal-title":"Front Immunol"},{"key":"8039_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11912-024-01622-6","volume":"27","author":"L Gamrath","year":"2025","unstructured":"Gamrath L, Pedersen TB, M\u00f8ller MV et al (2025) Role of the microbiome and diet for response to cancer checkpoint immunotherapy: a narrative review of clinical trials. Curr Oncol Rep 27:45\u201358","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"8039_CR7","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","volume":"28","author":"RC Simpson","year":"2022","unstructured":"Simpson RC, Shanahan ER, Batten M et al (2022) Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med 28(11):2344\u20132352. https:\/\/doi.org\/10.1038\/s41591-022-01965-2","journal-title":"Nat Med"},{"issue":"6","key":"8039_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.immuni.2014.05.014","volume":"40","author":"AN Thorburn","year":"2014","unstructured":"Thorburn AN, Macia L, Mackay CR (2014) Diet, metabolites, and \u201cWestern-Lifestyle\u201d inflammatory diseases. Immunity 40(6):833\u2013842. https:\/\/doi.org\/10.1016\/j.immuni.2014.05.014","journal-title":"Immunity"},{"key":"8039_CR9","doi-asserted-by":"publisher","DOI":"10.1017\/jns.2020.31","volume":"9","author":"F Genel","year":"2020","unstructured":"Genel F, Kale M, Pavlovic N et al (2020) Health effects of a low-inflammatory diet in adults with arthritis: a systematic review and meta-analysis. J Nutr Sci 9:e37. https:\/\/doi.org\/10.1017\/jns.2020.31","journal-title":"J Nutr Sci"},{"key":"8039_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.985732","volume":"9","author":"SH Overgaard","year":"2022","unstructured":"Overgaard SH, S\u00f8rensen SB, Munk HL et al (2022) Impact of fibre and red\/processed meat intake on treatment outcomes among patients with chronic inflammatory diseases initiating biological therapy: a prospective cohort study. Front Nutr 9:985732. https:\/\/doi.org\/10.3389\/fnut.2022.985732","journal-title":"Front Nutr"},{"key":"8039_CR11","unstructured":"Athlisis Health Development (2025) Athlisis. In: Athlisis Heal. Dev. Athens, Greece. https:\/\/www.athlisis.com\/. Accessed 4 Jan 2026"},{"issue":"6","key":"8039_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1590\/1678-98652018000600006","volume":"31","author":"B Gorgulho","year":"2018","unstructured":"Gorgulho B, Pot GK, Sarti FM et al (2018) Measuring the quality of main meals: validation of a meal quality index. Rev Nutr 31(6):567\u2013575. https:\/\/doi.org\/10.1590\/1678-98652018000600006","journal-title":"Rev Nutr"},{"key":"8039_CR13","unstructured":"R Core Team. (2016) R: A Language and Environment for Statistical Computing. In: R Found. Stat. Comput. Vienna, Austria. https:\/\/www.r-project.org\/. Accessed 4 Jan 2026"},{"issue":"28","key":"8039_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011376","volume":"97","author":"M Figueiredo-Braga","year":"2018","unstructured":"Figueiredo-Braga M, Cornaby C, Cortez A et al (2018) Depression and anxiety in systemic lupus erythematosus. Medicine (Baltimore) 97(28):e11376. https:\/\/doi.org\/10.1097\/MD.0000000000011376","journal-title":"Medicine (Baltimore)"},{"issue":"07","key":"8039_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.4088\/JCP.11r07425","volume":"73","author":"ZS Meszaros","year":"2012","unstructured":"Meszaros ZS, Perl A, Faraone SV (2012) Psychiatric symptoms in systemic lupus erythematosus. J Clin Psychiatry 73(07):993\u20131001. https:\/\/doi.org\/10.4088\/JCP.11r07425","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"8039_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/09612033211063795","volume":"31","author":"A Knippenberg","year":"2022","unstructured":"Knippenberg A, Robinson GA, Wincup C et al (2022) Plant-based dietary changes may improve symptoms in patients with systemic lupus erythematosus. Lupus 31(1):65\u201376. https:\/\/doi.org\/10.1177\/09612033211063795","journal-title":"Lupus"},{"issue":"4","key":"8039_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/children10040697","volume":"10","author":"MG Grammatikopoulou","year":"2023","unstructured":"Grammatikopoulou MG, Syrmou V, Lioliopoulou M-L et al (2023) Anorexia nervosa in juvenile systemic lupus erythematosus (SLE): a causality dilemma. Children 10(4):697. https:\/\/doi.org\/10.3390\/children10040697","journal-title":"Children"},{"issue":"9","key":"8039_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/fsn3.70890","volume":"13","author":"X Zhang","year":"2025","unstructured":"Zhang X, Fan G (2025) The anti-lupus plate: mapping nutritional interventions to inflammatory pathways in systemic lupus erythematosus. Food Sci Nutr 13(9):e70890. https:\/\/doi.org\/10.1002\/fsn3.70890","journal-title":"Food Sci Nutr"},{"issue":"2\u20133","key":"8039_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jpc.16523","volume":"60","author":"JX Wang","year":"2024","unstructured":"Wang JX, Adamson J, Major GA (2024) Contemporaneous onset of systemic lupus erythematosus and severe eating disorder; neither the chicken nor the egg. J Paediatr Child Health 60(2\u20133):67\u201368. https:\/\/doi.org\/10.1111\/jpc.16523","journal-title":"J Paediatr Child Health"},{"key":"8039_CR20","doi-asserted-by":"publisher","unstructured":"Kudsi M, Tarcha R, Khalayli N, et al (2024) Anorexia nervosa and systemic lupus erythematosus: a coincidence? Int J Surg Glob Heal 7(3). https:\/\/doi.org\/10.1097\/GH9.0000000000000448","DOI":"10.1097\/GH9.0000000000000448"},{"issue":"1","key":"8039_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5114\/ceji.2021.104326","volume":"46","author":"L Hyla-Klekot","year":"2021","unstructured":"Hyla-Klekot L, Wolny A, Janas-Kozik MM, Koszutski T (2021) Anorexia nervosa and juvenile lupus erythematosus in a 16-year-old female patient \u2013 common disease origin or random coincidence? Cent Eur J Immunol 46(1):127\u2013132. https:\/\/doi.org\/10.5114\/ceji.2021.104326","journal-title":"Cent Eur J Immunol"},{"issue":"7","key":"8039_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/09612033251332830","volume":"34","author":"JC da Mota","year":"2025","unstructured":"da Mota JC, Smaira FI, Julio JMG et al (2025) Association between excess body weight and disordered eating attitude among women living with systemic lupus erythematosus. Lupus 34(7):657\u2013665. https:\/\/doi.org\/10.1177\/09612033251332830","journal-title":"Lupus"},{"key":"8039_CR23","doi-asserted-by":"crossref","unstructured":"Pardali EC, Kontouli KM, Gkouvi A et al (2026) Systemic lupus erythematosus is associated with an increased risk for orthorexia nervosa: a cross-sectional study. Rheumatol Int (in press).","DOI":"10.1007\/s00296-026-06107-2"},{"issue":"1","key":"8039_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00653-y","volume":"11","author":"I Parodis","year":"2025","unstructured":"Parodis I, Rovin BH, Tektonidou MG et al (2025) Lupus nephritis. Nat Rev Dis Primers 11(1):69. https:\/\/doi.org\/10.1038\/s41572-025-00653-y","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"8039_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.kint.2023.09.001","volume":"105","author":"BH Rovin","year":"2024","unstructured":"Rovin BH, Ayoub IM, Chan TM et al (2024) Executive summary of the KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int 105(1):31\u201334. https:\/\/doi.org\/10.1016\/j.kint.2023.09.001","journal-title":"Kidney Int"},{"issue":"1","key":"8039_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.55563\/clinexprheumatol\/3f60yv","volume":"43","author":"J Fournier","year":"2024","unstructured":"Fournier J, Boussat B, Dervaux B et al (2024) Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis. Clin Exp Rheumatol 43(1):62\u201369. https:\/\/doi.org\/10.55563\/clinexprheumatol\/3f60yv","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"8039_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13075-024-03375-w","volume":"26","author":"X Leng","year":"2024","unstructured":"Leng X, Leszczy\u0144ski P, Jeka S et al (2024) A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806\/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotr. Arthritis Res Ther 26(1):157. https:\/\/doi.org\/10.1186\/s13075-024-03375-w","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"8039_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/reum\/218349","volume":"64","author":"A Gkouvi","year":"2026","unstructured":"Gkouvi A, Patrikiou E, Grammatikopoulou MG, Bogdanos DP (2026) Janus kinase inhibitors in giant cell arteritis: unmet needs and new challenges. Rheumatology 64(1):1\u20133. https:\/\/doi.org\/10.5114\/reum\/218349","journal-title":"Rheumatology"},{"key":"8039_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1470488","volume":"16","author":"S Parisi","year":"2025","unstructured":"Parisi S, Ditto MC, Ghellere F et al (2025) Update on tocilizumab in rheumatoid arthritis: a narrative review. Front Immunol 16:1470488. https:\/\/doi.org\/10.3389\/fimmu.2025.1470488","journal-title":"Front Immunol"},{"issue":"22","key":"8039_CR30","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e155","volume":"35","author":"IA Choi","year":"2020","unstructured":"Choi IA, Sagawa A, Lee EY et al (2020) Tocilizumab increases body weight and serum adipokine levels in patients with rheumatoid arthritis independently of their treatment response: a retrospective cohort study. J Korean Med Sci 35(22):e155. https:\/\/doi.org\/10.3346\/jkms.2020.35.e155","journal-title":"J Korean Med Sci"},{"issue":"2","key":"8039_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cyto.2012.11.007","volume":"61","author":"S Younis","year":"2013","unstructured":"Younis S, Rosner I, Rimar D et al (2013) Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-\u03b1 in patients with inflammatory rheumatic disorders: a 16-week comparative study. Cytokine 61(2):353\u2013355. https:\/\/doi.org\/10.1016\/j.cyto.2012.11.007","journal-title":"Cytokine"},{"issue":"2","key":"8039_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/rheumatology\/keae500","volume":"64","author":"MF Tsoi","year":"2025","unstructured":"Tsoi MF, Kearsley-Fleet L, Azadbakht N et al (2025) Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA. Rheumatology 64(2):477\u2013483. https:\/\/doi.org\/10.1093\/rheumatology\/keae500","journal-title":"Rheumatology"},{"issue":"6","key":"8039_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16665","volume":"9","author":"M Berman","year":"2023","unstructured":"Berman M, Berliner S, Bashouti N et al (2023) Reduced C-reactive protein level at hospital admission in patients treated with tocilizumab \u2013 an attention may be required. Heliyon 9(6):e16665. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16665","journal-title":"Heliyon"},{"key":"8039_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-010423","volume":"2013","author":"SF Bari","year":"2013","unstructured":"Bari SF, Khan A, Lawson T (2013) C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. BMJ Case Rep 2013:bcr2013010423. https:\/\/doi.org\/10.1136\/bcr-2013-010423","journal-title":"BMJ Case Rep"},{"issue":"1","key":"8039_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S et al (2020) 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79(1):19\u201330. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215672","journal-title":"Ann Rheum Dis"},{"key":"8039_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2022.103202","volume":"36","author":"J Bini","year":"2022","unstructured":"Bini J, Parikh L, Lacadie C et al (2022) Stress-level glucocorticoids increase fasting hunger and decrease cerebral blood flow in regions regulating eating. NeuroImage: Clinical 36:103202. https:\/\/doi.org\/10.1016\/j.nicl.2022.103202","journal-title":"NeuroImage: Clinical"},{"issue":"3","key":"8039_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nutres.2013.12.006","volume":"34","author":"BS Berthon","year":"2014","unstructured":"Berthon BS, MacDonald-Wicks LK, Wood LG (2014) A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans. Nutr Res 34(3):179\u2013190. https:\/\/doi.org\/10.1016\/j.nutres.2013.12.006","journal-title":"Nutr Res"},{"key":"8039_CR38","unstructured":"Arthritis UK Tocilizumab. https:\/\/www.arthritis-uk.org\/information-and-support\/understanding-arthritis\/arthritis-treatments\/drugs\/tocilizumab\/. Accessed 12 Jan 2026"},{"key":"8039_CR39","unstructured":"Genentech USA SJIA Clinical Trial Safety Profile Side Effects | ACTEMRA\u00ae (tocilizumab). https:\/\/www.actemrahcp.com\/sjia\/safety-profile.html. Accessed 12 Jan 2026"},{"issue":"17","key":"8039_CR40","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ (2017) Tocilizumab: a review in rheumatoid arthritis. Drugs 77(17):1865\u20131879. https:\/\/doi.org\/10.1007\/s40265-017-0829-7","journal-title":"Drugs"},{"issue":"2","key":"8039_CR41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","volume":"51","author":"R Spiera","year":"2021","unstructured":"Spiera R, Unizony SH, Bao M et al (2021) Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum 51(2):469\u2013476. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.03.006","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"8039_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13873","volume":"27","author":"Y Ting-Ting","year":"2024","unstructured":"Ting-Ting Y, Wen-Jing T, Yi-Ting L et al (2024) Eating is like experiencing a gamble\u2019: a qualitative study exploring the dietary decision-making process in adults with inflammatory bowel disease. Health Expect 27(1):e13873. https:\/\/doi.org\/10.1111\/hex.13873","journal-title":"Health Expect"},{"issue":"1","key":"8039_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03126-3","volume":"25","author":"E Hulander","year":"2023","unstructured":"Hulander E, Zverkova Sandstr\u00f6m T, Beckman Rehnman J et al (2023) Patients with radiographic axial spondylarthritis have an impaired dietary intake\u2014a cross-sectional study with matched controls from northern Sweden. Arthritis Res Ther 25(1):142. https:\/\/doi.org\/10.1186\/s13075-023-03126-3","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"8039_CR44","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/annrheumdis-2024-eular.468","volume":"83","author":"E Hulander","year":"2024","unstructured":"Hulander E, Hallstr\u00f6m M, Deminger A et al (2024) POS0499 impaired dietary intake in patients with radiographic axial spondyloarthritis and its relation to disease activity and physical function: a multi-regional cross-sectional study. Ann Rheum Dis 83(Suppl 1):897\u2013898. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.468","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"8039_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/nu14224730","volume":"14","author":"P Vergne-Salle","year":"2022","unstructured":"Vergne-Salle P, Salle L, Fressinaud-Marie AC et al (2022) Diet and disease activity in patients with axial spondyloarthritis: SpondyloArthritis and NUTrition Study (SANUT). Nutrients 14(22):4730. https:\/\/doi.org\/10.3390\/nu14224730","journal-title":"Nutrients"},{"key":"8039_CR46","unstructured":"OncoLink Rituximab (Rituxan\u00ae). https:\/\/www.oncolink.org\/cancer-treatment\/oncolink-rx\/rituximab-rituxan-R. Accessed 12 Jan 2026"},{"key":"8039_CR47","unstructured":"CDC Safer Food Choices for People With Weakened Immune Systems | Food Safety. https:\/\/www.cdc.gov\/food-safety\/foods\/weakened-immune-systems.html. Accessed 12 Jan 2026"},{"issue":"1","key":"8039_CR48","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/cam4.1166","volume":"7","author":"S Hohaus","year":"2018","unstructured":"Hohaus S, Tisi MC, Bellesi S et al (2018) Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. Cancer Med 7(1):270\u2013281. https:\/\/doi.org\/10.1002\/cam4.1166","journal-title":"Cancer Med"},{"issue":"4","key":"8039_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-006079","volume":"11","author":"EJF Santos","year":"2025","unstructured":"Santos EJF, Farisogullari B, Fishpool K et al (2025) Instruments for measuring fatigue in people with rheumatic and musculoskeletal diseases: a systematic review of measurement properties. RMD Open 11(4):e006079. https:\/\/doi.org\/10.1136\/rmdopen-2025-006079","journal-title":"RMD Open"},{"issue":"1","key":"8039_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.tins.2013.10.003","volume":"37","author":"R Dantzer","year":"2014","unstructured":"Dantzer R, Heijnen CJ, Kavelaars A et al (2014) The neuroimmune basis of fatigue. Trends Neurosci 37(1):39\u201346. https:\/\/doi.org\/10.1016\/j.tins.2013.10.003","journal-title":"Trends Neurosci"},{"key":"8039_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2018.00078","volume":"12","author":"TE Lacourt","year":"2018","unstructured":"Lacourt TE, Vichaya EG, Chiu GS et al (2018) The high costs of low-grade inflammation: persistent fatigue as a consequence of reduced cellular-energy availability and non-adaptive energy expenditure. Front Behav Neurosci 12:343884. https:\/\/doi.org\/10.3389\/fnbeh.2018.00078","journal-title":"Front Behav Neurosci"},{"issue":"2","key":"8039_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1017\/S000711450769936X","volume":"98","author":"P Li","year":"2007","unstructured":"Li P, Yin YL, Li D et al (2007) Amino acids and immune function. Br J Nutr 98(2):237\u2013252. https:\/\/doi.org\/10.1017\/S000711450769936X","journal-title":"Br J Nutr"},{"issue":"5","key":"8039_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13050134","volume":"13","author":"EC Pardali","year":"2025","unstructured":"Pardali EC, Klonizakis M, Goulis DG et al (2025) Sarcopenia in rheumatic diseases: a hidden issue of concern. Dis (Basel, Switzerland) 13(5):134. https:\/\/doi.org\/10.3390\/diseases13050134","journal-title":"Dis (Basel, Switzerland)"},{"issue":"7","key":"8039_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181086","volume":"12","author":"ML Crouch","year":"2017","unstructured":"Crouch ML, Knowels G, Stuppard R et al (2017) Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects. PLoS One 12(7):e0181086. https:\/\/doi.org\/10.1371\/journal.pone.0181086","journal-title":"PLoS One"},{"issue":"4","key":"8039_CR55","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5114\/reum.2021.108430","volume":"59","author":"SG Al Khayyat","year":"2021","unstructured":"Al Khayyat SG, Falsetti P, Conticini E et al (2021) Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis - retrospective study. Reumatologia 59(4):206\u2013210. https:\/\/doi.org\/10.5114\/reum.2021.108430","journal-title":"Reumatologia"},{"issue":"9","key":"8039_CR56","doi-asserted-by":"publisher","first-page":"S507","DOI":"10.1016\/j.jtho.2022.07.893","volume":"17","author":"RJE Skipworth","year":"2022","unstructured":"Skipworth RJE, Bonomi PD, Currow DC et al (2022) EP10.01\u2013016 cachexia\u2019s impact on immunotherapy dose reduction, treatment discontinuation, and survival: a systematic review. J Thorac Oncol 17(9):S507. https:\/\/doi.org\/10.1016\/j.jtho.2022.07.893","journal-title":"J Thorac Oncol"},{"issue":"4","key":"8039_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041076","volume":"15","author":"C Madeddu","year":"2023","unstructured":"Madeddu C, Busquets S, Donisi C et al (2023) Effect of cancer-related cachexia and associated changes in nutritional status, inflammatory status, and muscle mass on immunotherapy efficacy and survival in patients with advanced non-small cell lung cancer. Cancers (Basel) 15(4):1076. https:\/\/doi.org\/10.3390\/cancers15041076","journal-title":"Cancers (Basel)"},{"key":"8039_CR58","unstructured":"2025 Dietary Guidelines Advisory Committee (2024) Scientific Report of the 2025 Dietary Guidelines Advisory Committee: Advisory Report to the Secretary of Health and Human Services and Secretary of Agriculture. Washington, DC"},{"issue":"1","key":"8039_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0586-3","volume":"16","author":"L Navarini","year":"2017","unstructured":"Navarini L, Afeltra A, Gallo Afflitto G, Margiotta DPE (2017) Polyunsaturated fatty acids: any role in rheumatoid arthritis? Lipids Health Dis 16(1):197. https:\/\/doi.org\/10.1186\/s12944-017-0586-3","journal-title":"Lipids Health Dis"},{"issue":"3","key":"8039_CR60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0304-3835(90)90184-Y","volume":"52","author":"H Gabor","year":"1990","unstructured":"Gabor H, Blank EW, Ceriani RL (1990) Effect of dietary fat and monoclonal antibody therapy on the growth of human mammary adenocarcinoma MX-1 grafted in athymic mice. Cancer Lett 52(3):173\u2013178. https:\/\/doi.org\/10.1016\/0304-3835(90)90184-Y","journal-title":"Cancer Lett"},{"issue":"16_suppl","key":"8039_CR61","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1200\/JCO.2025.43.16_suppl.2567","volume":"43","author":"E Rafie","year":"2025","unstructured":"Rafie E, Hunter S, Benlaifaoui M et al (2025) Dietary compounds and patterns associated with immune checkpoint inhibitor (ICI) outcomes in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 43(16_suppl):2567\u20132567. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.2567","journal-title":"J Clin Oncol"},{"issue":"4","key":"8039_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06641-6","volume":"15","author":"A Golonko","year":"2024","unstructured":"Golonko A, Pienkowski T, Swislocka R et al (2024) Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review. Cell Death Dis 15(4):254. https:\/\/doi.org\/10.1038\/s41419-024-06641-6","journal-title":"Cell Death Dis"},{"issue":"1","key":"8039_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03867-3","volume":"74","author":"VE Stefan","year":"2024","unstructured":"Stefan VE, Weber DD, Lang R, Kofler B (2024) Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade. Cancer Immunol Immunother 74(1):23. https:\/\/doi.org\/10.1007\/s00262-024-03867-3","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"8039_CR64","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1017\/S095442241700004X","volume":"30","author":"AM Stephen","year":"2017","unstructured":"Stephen AM, Champ MMJ, Cloran SJ et al (2017) Dietary fibre in Europe: current state of knowledge on definitions, sources, recommendations, intakes and relationships to health. Nutr Res Rev 30(2):149\u2013190. https:\/\/doi.org\/10.1017\/S095442241700004X","journal-title":"Nutr Res Rev"},{"issue":"5","key":"8039_CR65","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jamaoncol.2022.7753","volume":"9","author":"LA Bolte","year":"2023","unstructured":"Bolte LA, Lee KA, Bj\u00f6rk JR et al (2023) Association of a Mediterranean diet with outcomes for patients treated with immune checkpoint blockade for advanced melanoma. JAMA Oncol 9(5):705. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7753","journal-title":"JAMA Oncol"},{"key":"8039_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.645500","volume":"12","author":"B Zhao","year":"2021","unstructured":"Zhao B, Zhou B, Dong C et al (2021) Lactobacillus reuteri alleviates gastrointestinal toxicity of rituximab by regulating the proinflammatory T cells in vivo. Front Microbiol 12:645500. https:\/\/doi.org\/10.3389\/fmicb.2021.645500","journal-title":"Front Microbiol"},{"issue":"5","key":"8039_CR67","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41590-023-01512-2","volume":"24","author":"NJ Bernard","year":"2023","unstructured":"Bernard NJ (2023) Probiotics boost immunotherapy. Nat Immunol 24(5):732\u2013732. https:\/\/doi.org\/10.1038\/s41590-023-01512-2","journal-title":"Nat Immunol"},{"issue":"12","key":"8039_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14124193","volume":"14","author":"K Grafanaki","year":"2025","unstructured":"Grafanaki K, Maniatis A, Anastogianni A et al (2025) Nutrition and diet patterns as key modulators of metabolic reprogramming in melanoma immunotherapy. J Clin Med 14(12):4193. https:\/\/doi.org\/10.3390\/jcm14124193","journal-title":"J Clin Med"},{"issue":"2","key":"8039_CR69","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/19490976.2017.1290756","volume":"8","author":"HD Holscher","year":"2017","unstructured":"Holscher HD (2017) Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes 8(2):172\u2013184. https:\/\/doi.org\/10.1080\/19490976.2017.1290756","journal-title":"Gut Microbes"},{"issue":"6371","key":"8039_CR70","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"key":"8039_CR71","unstructured":"ClinicalTrials.gov Study Details | NCT06475807 | Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors. https:\/\/clinicaltrials.gov\/study\/NCT06475807. Accessed 14 Jan 2026"},{"issue":"1","key":"8039_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13234-1","volume":"24","author":"RM Farias","year":"2024","unstructured":"Farias RM, Jiang Y, Levy EJ et al (2024) Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy. BMC Cancer 24(1):1493. https:\/\/doi.org\/10.1186\/s12885-024-13234-1","journal-title":"BMC Cancer"},{"key":"8039_CR73","unstructured":"Arthritis UK Abatacept | Side-effects, uses, time to work. https:\/\/www.arthritis-uk.org\/information-and-support\/understanding-arthritis\/arthritis-treatments\/drugs\/abatacept\/. Accessed 11 Jan 2026"},{"key":"8039_CR74","unstructured":"European Medicines Agency Abatacept. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orencia-epar-product-information_en.pdf. Accessed 11 Jan 2026"},{"key":"8039_CR75","unstructured":"European Medicines Agency Benlysta. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benlysta-epar-product-information_en.pdf. Accessed 11 Jan 2026"},{"key":"8039_CR76","unstructured":"Arthritis UK Belimumab | Side effects, uses, time to work. https:\/\/www.arthritis-uk.org\/information-and-support\/understanding-arthritis\/arthritis-treatments\/drugs\/belimumab\/. Accessed 11 Jan 2026"},{"issue":"1","key":"8039_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0339757","volume":"21","author":"H Zhang","year":"2026","unstructured":"Zhang H, Lin M, Zhao D, Fu Y (2026) Adverse events associated with cyclophosphamide: a pharmacovigilance study using the FDA adverse event reporting system. PLoS One 21(1):e0339757. https:\/\/doi.org\/10.1371\/journal.pone.0339757","journal-title":"PLoS One"},{"key":"8039_CR78","unstructured":"Arthritis UK Cyclophosphamide | Side-effects, uses, time to work. https:\/\/www.arthritis-uk.org\/information-and-support\/understanding-arthritis\/arthritis-treatments\/drugs\/cyclophosphamide\/. Accessed 11 Jan 2026"},{"key":"8039_CR79","unstructured":"OncoLink Cyclophosphamide Oral Formulation (Cytoxan\u00ae, Neosar\u00ae, Endoxan\u00ae) | OncoLink. https:\/\/www.oncolink.org\/cancer-treatment\/oncolink-rx\/cyclophosphamide-oral-formulation-cytoxan-R-neosar-R-endoxan-R. Accessed 6 Mar 2026"},{"issue":"6","key":"8039_CR80","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1310\/hpj4806-489","volume":"48","author":"AA Auten","year":"2013","unstructured":"Auten AA, Beauchamp LN, Taylor J, Hardinger KL (2013) Hidden sources of grapefruit in beverages: potential interactions with immunosuppressant medications. Hosp Pharm 48(6):489\u2013493. https:\/\/doi.org\/10.1310\/hpj4806-489","journal-title":"Hosp Pharm"},{"key":"8039_CR81","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/B978-0-12-824315-2.00542-X","volume-title":"Encyclopedia of Toxicology","author":"CM Stork","year":"2024","unstructured":"Stork CM, Schreffler SM (2024) Cyclophosphamide. In: Stork CM, Schreffler SM (eds) Encyclopedia of Toxicology. Elsevier Inc., Fourth, pp 417\u2013421"},{"issue":"12","key":"8039_CR82","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725\u20133732. https:\/\/doi.org\/10.1182\/blood-2005-01-0016","journal-title":"Blood"},{"issue":"17","key":"8039_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/nu17172838","volume":"17","author":"I Konstantinidis","year":"2025","unstructured":"Konstantinidis I, Tsokkou S, Gavriilaki E et al (2025) Protective role of key micronutrients in chemotherapy-induced organ toxicity: a comprehensive review of mechanistic insights and clinical implications. Nutrients 17(17):2838. https:\/\/doi.org\/10.3390\/nu17172838","journal-title":"Nutrients"},{"key":"8039_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.02.016","author":"RA Hansen","year":"2007","unstructured":"Hansen RA, Gartlehner G, Powell GE, Sandler RS (2007) Serious adverse events with Infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 5(6):729\u2013735.\u00a0https:\/\/doi.org\/10.1016\/j.cgh.2007.02.016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8039_CR85","unstructured":"Arthritis UK Infliximab. https:\/\/www.arthritis-uk.org\/information-and-support\/understanding-arthritis\/arthritis-treatments\/drugs\/infliximab\/. Accessed 12 Jan 2026"},{"key":"8039_CR86","unstructured":"Pfizer Medical - US Inflectra (infliximab-dyyb) Adverse Reactions. https:\/\/www.pfizermedical.com\/inflectra\/adverse-reactions#S6.1. Accessed 12 Jan 2026"},{"key":"8039_CR87","unstructured":"Celltrion Healthcare Co. Ltd. INFLECTRA \u00ae Product Monograph. https:\/\/pdf.hres.ca\/dpd_pm\/00042037.PDF. Accessed 12 Jan 2026"},{"key":"8039_CR88","unstructured":"Johnson & Johnson Health Care Systems Inc. (2024) Understanding Your Treatment With REMICADE\u00ae or Infliximab. https:\/\/www.remicade.com\/assets\/pdf\/Patient_Brochure.pdf. Accessed 12 Jan 2026"},{"issue":"3","key":"8039_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/nu9030286","volume":"9","author":"V Andersen","year":"2017","unstructured":"Andersen V, Hansen AK, Heitmann BL (2017) Potential impact of diet on treatment effect from anti-TNF drugs in inflammatory bowel disease. Nutrients 9(3):286. https:\/\/doi.org\/10.3390\/nu9030286","journal-title":"Nutrients"},{"issue":"1","key":"8039_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11010138","volume":"11","author":"M Liso","year":"2022","unstructured":"Liso M, Sila A, Verna G et al (2022) Nutritional regimes enriched with antioxidants as an efficient adjuvant for IBD patients under Infliximab administration, a pilot study. Antioxidants 11(1):138. https:\/\/doi.org\/10.3390\/antiox11010138","journal-title":"Antioxidants"},{"key":"8039_CR91","unstructured":"Arumugham VB, Rayi A (2015) Intravenous Immunoglobulin (IVIG). StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554446\/. Accessed 14 Mar 2026"},{"key":"8039_CR92","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","volume":"122","author":"FA Bonilla","year":"2008","unstructured":"Bonilla FA (2008) Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 122(6):1238\u20131239. https:\/\/doi.org\/10.1016\/j.jaci.2008.08.033","journal-title":"J Allergy Clin Immunol"},{"issue":"JUN","key":"8039_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z (2018) Adverse effects of immunoglobulin therapy. Front Immunol 9(JUN):1299. https:\/\/doi.org\/10.3389\/fimmu.2018.01299","journal-title":"Front Immunol"},{"issue":"4","key":"8039_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/cc11304","volume":"16","author":"PM Kasi","year":"2012","unstructured":"Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS (2012) Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care 16(4):231. https:\/\/doi.org\/10.1186\/cc11304","journal-title":"Crit Care"},{"key":"8039_CR95","unstructured":"Hanif N, Anwer F (2025) Rituximab. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL), pp 233\u2013239. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564374\/. Accessed 14 Mar 2026"},{"key":"8039_CR96","doi-asserted-by":"publisher","unstructured":"Nagy S, Hussein A, Kesselman MM (2025) The Importance of timing in immunotherapy: a systematic review. Cureus 17(4):e82994. https:\/\/doi.org\/10.7759\/cureus.82994","DOI":"10.7759\/cureus.82994"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08039-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08039-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08039-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:26:02Z","timestamp":1780982762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08039-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8039"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08039-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures followed ethical standards per the 1964 Helsinki Declaration and its amendments. The study was approved by the Larissa University Hospital Scientific Board (30\/3rd\/20\u201302-2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients for the publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Preliminary results of this study (with less participants and fewer analyses) were submitted as an abstract at the EULAR 2026 Congress.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}